Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection.
BACKGROUND & AIMS
There is controversy regarding whether nucleos(t)ide analogues contribute to renal impairment in patients with chronic hepatitis B virus (HBV) infection. We analyzed changes in renal function in patients with chronic HBV infection and whether these were associated with treatment or comorbidities.


METHODS
We performed a longitudinal observational study to investigate factors associated with renal function in 214 patients (median age, 43 y; 69.2% men) with compensated chronic HBV monoinfection treated with 343 lines of nucleos(t)ide analogues (210 monotherapies, 133 combinations) between 1990 and 2012 (median time, 2.4 y) in France. A linear mixed-effect model was used to model variations of estimated glomerular filtration rate (eGFR, computed with the Chronic Kidney Disease Epidemiology Collaboration formula), adjusting for age, sex, geographic origin, initial liver fibrosis, level of HBV DNA, and an eGFR less than 90 mL/min/1.73 m(2).


RESULTS
The eGFR decreased in patients given adefovir dipivoxil as monotherapy or in a combination (P < .0001 and P < .002, respectively), and remained stable in patients given lamivudine, tenofovir disoproxil fumarate, or entecavir. The eGFR decreased in patients with a baseline eGFR of less than 90 mL/min/1.73 m2, regardless of treatment. The eGFR remained stable or increased, regardless of treatment, in patients with a baseline eGFR of 90 mL/min/1.73 m2 or greater and with an initial HBV DNA level of 100,000 IU/mL or greater. Patients born in areas of high endemicity of HBV were more prone to increases in eGFR with treatment.


CONCLUSIONS
In a real-life study, the eGFR remained stable or increased over time in patients with chronic HBV monoinfection with a baseline eGFR of 90 mL/min/1.73 m2 or higher and treated with tenofovir disoproxil fumarate or entecavir. Patients born in an area of high endemicity of HBV who had initial levels of HBV DNA of 100,000 IU/mL or greater were more likely to have increased eGFR with treatment.
['Mallet|Vincent|V|', 'Schwarzinger|Michaël|M|', 'Vallet-Pichard|Anaïs|A|', 'Fontaine|Hélène|H|', 'Corouge|Marion|M|', 'Sogni|Philippe|P|', 'Pol|Stanislas|S|']
D000328:Adult D000998:Antiviral Agents D005260:Female D005602:France D005919:Glomerular Filtration Rate D006147:Guanine D019694:Hepatitis B, Chronic D006801:Humans D007668:Kidney D008137:Longitudinal Studies D008297:Male D008875:Middle Aged D000068698:Tenofovir
Chronic Kidney Disease Antiviral BeSafe Study Drug Mixed Linear Model